PDCD1 and lung carcinoma: PD-L1 determines response to immunotherapy in lung cancer and to a lesser extent in melanoma [10,11] since it influences immune tolerance [12,13] and can be blocked by anti-programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors [3].